Patents by Inventor Thomas W. Doebber

Thomas W. Doebber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceuticals for treating obesity
    Publication number: 20030032581
    Abstract: Compounds which are antagonists of strong PPAR-gamma agonists, such as rosiglitazone, and are also partial agonists of the PPAR-gamma receptor, are active agents for correcting or reducing obesity. For example, 1-(p-chlorobenzyl)-5-chloro-3-thiophenylindole-2-carboxylic acid, is characterized as being a potent and selective ligand for PPAR-gamma which has partial agonist (<30% maximal effects relative to rosiglitazone) and antagonist activity in cell-free and cell-based assays for the PPAR-gamma receptor. The compound is a potent agent for reducing obesity and insulin resistance in fat-fed C57BL/6J mice. This compound and other PPAR-gamma antagonists/partial agonists and pharmaceutically acceptable salts are effective in the treatment of obesity and/or diabetes and/or insulin resistance.
    Type: Application
    Filed: September 11, 2002
    Publication date: February 13, 2003
    Inventors: Joel P. Berger, Thomas W. Doebber, Mark D. Leibowitz, David E. Moller, Ralph T. Mosley, Richard L. Tolman, John Ventre, Bei B. Zhang, Gaochao Zhou
  • Method of treating diabetes and related disease states
    Patent number: 6020382
    Abstract: The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: February 1, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Thomas W. Doebber, Joel P. Berger, Gregory D. Berger, Mark D. Leibowitz, David E. Moller, John T. Olson, Arthur A. Patchett, Richard B. Toupence
  • Method of treating diabetes and related disease states
    Patent number: 5847008
    Abstract: The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: December 8, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Thomas W. Doebber, Joel P. Berger, Gregory D. Berger, Mark D. Leibowitz, David E. Moller, John T. Olson, Arthur A. Patchett, Richard B. Toupence
  • Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
    Patent number: 4595693
    Abstract: Analogs of 2,5-Diaryl tetrahydrofurans which were substituted or unsubstituted at 3,4-positions were prepared.These compounds are found to have potent and specific PAF (Platelet Activating Factor) antagonistic activities and thereby useful in the treatment of various diseases or disorders mediated by the PAF, for example, inflammation, cardiovascular disorder, asthma, lung edema, adult respiratory distress syndrome, pain, and aggregation of platelets.
    Type: Grant
    Filed: June 4, 1984
    Date of Patent: June 17, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Biftu, Thomas W. Doebber, San-Bao Hwang, Thomas R. Beattie, Tsung-Ying Shen, Robert Stevenson
  • 2,5-Diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
    Patent number: 4539332
    Abstract: Analogs of 2,5-Diaryl tetrahydrofurans which were substituted or unsubstituted at 3,4-positions were prepared.These compounds are found to have potent and specific PAF (Platelet Activating Factor) antagonistic activities and thereby useful in the treatment of various diseases or disorders mediated by the PAF, for example, inflammation, cardiovascular disorder, asthma, lung edema, adult respiratory distress syndrome, pain, and aggregation of platelets.
    Type: Grant
    Filed: November 14, 1983
    Date of Patent: September 3, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Biftu, San-Bao Hwang, Thomas W. Doebber, Thomas R. Beattie, Tsung-Ying Shen